Ironwood begins Phase IIb trial of IW-3718 to treat refractory gastroesophageal reflux disease

US-based Ironwood Pharmaceuticals has started a Phase IIb clinical trial of IW-3718 in patients with refractory gastroesophageal reflux disease (GERD), a chronic condition.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news